H3-3B
H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
Overview
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin.
CIViC holds 2 clinical evidence items and 1 assertion across 3 variants. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.28, affected pathway 0.76, genetic association 0.00, somatic mutation 0.95).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
- 1 · What it is
H3-3B (Histone H3.3) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Melanoma and Diffuse midline glioma, H3 K27-altered.
- 2 · What goes wrong in cancer
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis.
- 3 · How drugs use it
No product in this corpus aims at H3-3B yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:4765 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P84243 (protein name, function text, keywords and locations (REST API)); CIViC gene H3-3B (2 evidence items, 1 assertions, 3 variants; diseases: Chondroblastoma, Diffuse Midline Glioma, H3 K27-altered (GraphQL API, CC0)); Open Targets ENSG00000132475 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: melanoma 0.63, skin cancer 0.55 (GraphQL API, CC0))
Biology
Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Location: Nucleus; Chromosome (UniProt). Locus 17q25.1 (HGNC).
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Melanoma: Open Targets association 0.63 with melanoma (MONDO_0005105)
- Diffuse midline glioma, H3 K27-altered: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Chondroblastoma.
Latest papers
topQuery for this target: (TITLE:"H3-3B" OR ABSTRACT:"H3-3B" OR TITLE:"H3.3 histone B" OR ABSTRACT:"H3.3 histone B" OR TITLE:"Histone H3.3" OR ABSTRACT:"Histone H3.3" OR TITLE:"H3.3B" OR ABSTRACT:"H3.3B" OR TITLE:"H3F3B" OR ABSTRACT:"H3F3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about H3-3B, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetH3C14
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC.
- TargetH3C2
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC, Open Targets Platform.
- TargetHistone H3.3 (H3-3A)
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), CIViC, Open Targets Platform.
- TrialA Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), Melanoma.
- TargetGD2 (disialoganglioside)
Shares Diffuse midline glioma, H3 K27-altered (including DIPG), Melanoma.